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Available online 29 August 2013Abstract Mesenchymal stem cells or multipotent mesenchymal stromal cells (MSCs) have been extensively investigated in small
animal models to treat both acute and chronic liver injuries. Mechanisms of action are not clearly elucidated but may include their
ability to differentiate into hepatocyte-like cells, to reduce inflammation, and to enhance tissue repair at the site of injury. This
approach is controversial and evidence in large animals is missing. Side effects of MSC infusion such as the contribution to a fibrotic
process have been reported in experimental settings. Nevertheless, MSCs moved quickly from bench to bedside and over 280
clinical trials are registered, of which 28 focus on the treatment of liver diseases. If no severe side-effects were observed so far,
long-term benefits remain uncertain. More preclinical data regarding mechanisms of action, long term safety and efficacy are
warranted before initiating large scale clinical application. The proposal of this review is to visit the current state of knowledge
regardingmechanisms behind the therapeutic effects of MSCs in the treatment of experimental liver diseases, to address questions
about efficacy and risk, and to discuss recent clinical advances involving MSC-based therapies.
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Mesenchymal stem cells (MSCs), also called multipotent
mesenchymal stromal cells, are adult progenitor cells
originating from neural crest and mesoderm (Slukvin and
Vodyanik, 2011; Vodyanik et al., 2010; Takashima et al.,
2007). Originally, MSCs were found to reside in the stromal
fraction of the bone marrow, wherein they contribute to
nonhematopoietic stromal cell renewal including osteo-
blasts, adipocytes and chondrocytes (Pittenger et al.,
1999; Friedenstein et al., 1976; Prockop, 1997). In addition
to their mesenchymal differentiation capacities, MSCs may
have a multidirectional differentiation potential and
differentiate into cell types normally derived from endo-
derm or ectoderm such as hepatocytes (Hong et al., 2005;
K.D. Lee et al., 2004; Snykers et al., 2009). Further, it
has been shown that MSCs can be immunosuppressive
(Bartholomew et al., 2002; Di Nicola et al., 2002; Glennie
et al., 2005; Krampera et al., 2003; Le Blanc et al., 2003;
Tse et al., 2003; Le Blanc and Ringden, 2005). Given these
remarkable properties, their easy accessibility and strong
in vitro expansion ability, MSCs were considered as an ideal
cell source for autologous stem-cell-based replacement
therapies. Horwitz et al. demonstrated their utility in the
treatment of osteogenesis imperfecta in children by taking
advantage of the bone microenvironment regeneration
capacities of MSCs (Horwitz et al., 1999). Children had
increased growth velocity and total body mineral content,
and fewer fractures. MSC capacity to regulate the immune
system has been investigated in diverse diseases; Le
Blanc et al. showed that systemically injected MSCs were
effective for the treatment of steroid resistant graft versus
host disease (GVHD) in bone marrow transplanted patients
(Le Blanc et al., 2004, 2008); of note, 55% of them had a
complete response with MSC-based treatment. Other beneficial
effects were observed in various clinical situations, such as
renal transplantation (as an induction therapy) (Tan et al.,
2012),multiple sclerosis (Karussis et al., 2010) or systemic lupus
erythematosus (as an adjuvant treatment) (Sun et al., 2009).
Currently, MSCs are investigated with the perspective to
treat both acute and chronic liver diseases. Some studies
provided experimental and clinical evidences suggesting
that transplantation of MSCs can sustain liver function in the
situation of an acute or chronic liver injury (Peng et al.,
2011; Li et al., 2012). However, the mechanisms of actionunderlying the anti-fibrotic effects are currently not well
understood and long term safety and efficacy of such
treatment remain to be determined. MSCs may carry a risk
of fibrotic reaction (Baertschiger et al., 2009; Forbes et al.,
2004; Li et al., 2009), malignant transformation (Casiraghi et
al., 2013) and virus transmission (Sundin et al., 2006, 2008)
that may not be outweighed by the clinical benefit. In this
context, large animal studies are needed to provide enough
valid data to allow large clinical trials to start.
The proposal of this review is to visit the current state
of knowledge regarding mechanisms responsible for the
therapeutic effects of MSCs in the treatment of experimental
liver diseases, to address questions regarding efficacy and
safety, and to discuss recent clinical advances involving
clinical MSC-based therapies.MSCs and their physiological function
In the late 1960s Friedenstein and colleagues described bone
marrow stromal cells and referred to themas nonhematopoietic
colony-forming-unit fibroblasts (Friedenstein et al., 1968,
1970). Later, these cells were found to renew themselves
and differentiate in vitro in osteoblasts, chondrocytes and
adipocytes (Pittenger et al., 1999; Friedenstein et al.,
1974, 1976). Multipotency and self­renewal being the
hallmarks of “stemness”, MSCs were recognized as osteo-
genic (i.e. nonhematopoietic) “stem” cells of the bone
marrow (Friedenstein et al., 1987), wherein they constitute
a small subset accounting for 0.001 to 0.01% of the cells.
However, their contribution to nonhematopoietic stromal cell
renewal in vivo was demonstrated much later (Morikawa
et al., 2009). The term “mesenchymal stem cells” was used
first by Caplan (1991). Later on, these cells were found to
reside in adipose tissue (Hauner et al., 1989; Zuk et al., 2002;
R.H. Lee et al., 2004), peripheral blood (Zvaifler et al., 2000;
Fernandez et al., 1997), umbilical cord blood (Erices et al.,
2000), various fetal tissues (in't Anker et al., 2003; da Silva
Meirelles et al., 2006), placenta (Fukuchi et al., 2004),
pancreas (Baertschiger et al., 2008) and liver (Najimi et al.,
2007). Thus, the term “mesenchymal stem cell” was used to
qualify stromal cells isolated following different protocols
and arising from diverse tissues. Facing the heterogeneity
of what was called “MSC”, the International Society of
Cellular Therapy (ISCT) proposed a new terminology, calling
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(Dominici et al., 2006). It was recommended to specify the
tissue origin of MSCs, e.g. bone marrow-derived MSCs and
adipose tissue-derived MSCs. The ISCT established criteria to
define MSCs: (i) plastic-adherent cells under standard culture
conditions, (ii) CD105, CD73 and CD90 positive, (iii) CD11b,
CD14, CD34, CD45, CD79a andHLA-DR negative, and (iv) ex-vivo
differentiation into osteocytes, adipocytes and chondrocytes
should be demonstrated.
In addition to their mesenchymal differentiation capac-
ities, MSCs have a multidirectional differentiation potential
including transdifferentiation into endothelial cells (Oswald
et al., 2004), cardiocytes (Makino et al., 1999), neurocytes
(Snykers et al., 2009; Weiss et al., 2006), insulin producing
beta-cells (Xie et al., 2009) and hepatocyte-like cells (Hong
et al., 2005; K.D. Lee et al., 2004; Snykers et al., 2009).
However, their differentiation into these types of cells
is still controversial. The major concern is the lack of repro-
ducibility in the generation of well differentiated cells which
might be explained by the use of different subpopulations of
MSC. Currently, standardized protocol for isolation, expansion
and characterization is not uniformly used by researchers.
Although it has been suggested that such transdifferentiation,
crossing lineage barrier, occurs in pathologic situations, to our
best knowledge, no evidence clearly demonstrated that such a
phenomenon can occur in a physiologic situation (Duncan et al.,
2009). Hepatocytes seemed to be renewed from small
hepatocyte-like progenitors (Gordon et al., 2000; Vig et al.,
2006) originating from a periportal niche and migrating to the
central vein (Fellous et al., 2009).
MSCs have been studied in much detail regarding
their differentiation potential and immunomodulatory
properties when transplanted as therapeutic agents, but
their physiologic role in vivo remains largely undefined
(Nombela-Arrieta et al., 2011). Their small number and
the lack of specific markers made them difficult to
identify in vivo until recently. Studies showed that they
constitute a population positive for CD146 present mainly
in the adventitia of microvessels (Morikawa et al., 2009;
Sacchetti et al., 2007). Furthermore, nestin marker was
reported to selectively label MSCs and allowed to confirm
their role as osteochondral progenitors (Mendez-Ferrer
et al., 2010). In the bone marrow MSCs provide soluble
factors and extracellular matrix proteins that promote
hematopoietic stem cell maintenance (Mendez-Ferrer et
al., 2010), and are possibly issued from blood vessel
pericyte (Hirschi and D'Amore, 1996; da Silva Meirelles
et al., 2009; Odorfer et al., 2011). Despite the fact that
MSCs possess both in vivo and in vitro immunomodulatory
activities (Nauta and Fibbe, 2007), no evidence exists to
date that these regulatory properties are an inherent role
of MSC in its native localization in the tissues. However, a
physiological role in immune regulation of MSCs in the bone
marrow is plausible, as it is the site where the adaptive
immune responses originate.
Mechanisms implicated in the therapeutic
effects of MSCs
Hereafter, wewill focus on the properties thatmay allowMSCs
to treat liver diseases. First, according to some investigators,MSCs are able to differentiate into hepatocyte-like cells
and thus to compensate for impaired liver function. Second,
MSCs have immunomodulatory properties and secrete anti-
inflammatory cytokine.MSCs as hepatocyte-like cells
Using specific culture conditions, some studies showed that
MSCs undergo a phenotypic change, express genes typically
expressed in hepatocytes, fulfill some metabolic functions
similar to hepatocyte, and thus postulated that MSCs can
transdifferentiate into hepatocyte-like cells in vitro (K.D.
Lee et al., 2004; Li et al., 2010; Ong et al., 2006; Banas et
al., 2007; Piryaei et al., 2011; Aurich et al., 2007; Campard
et al., 2008; Aurich et al., 2009).
First, it is crucial to define what characteristics are
needed for a differentiated cell to be comparable to a
primary hepatocyte. The minimal set of functions of a true
hepatocyte includes (Hengstler et al., 2005) (i) metabolic
function (detoxification of xenobiotics (i.e. diazepam,
lidocaine) and endogenous substances (i.e. ammonia));
(ii) synthetic function (i.e. albumin, clotting factors, comple-
ment, lipids); and (iii) storage (glycogen and fat soluble
vitamins). For example, a candidate hepatocyte-like
cell would be almost indistinguishable from a primary
hepatocyte if the following criteria are fulfilled: synthesis of
albumin, urea, and fibrinogen; functional cytochromes P450
2A6, 1A2, 2C9, 2B6, 2C19, 2D6, 3A4, and 2C8; and functional
uridine 5′-diphospho-glucuronosyltransferase, glutathione-S-
transferase, and sulfotransferase (Hengstler et al., 2005).
In addition to this, other markers such as α-fetoprotein,
cytokeratin-18, or hepatocyte nuclear factor 4 are used to
detect hepatocyte-like cells. However, taken individually,
these hepatic lineage markers are not restricted to the
liver; for example, cytokeratins are present in gastric cardia,
skin (Korbling et al., 2002), and lung (Schlichenmaier et al.,
2002); albumin and α-fetoprotein are detected in pancreas
(Beerheide et al., 2002). Overall, RNA and protein analyses
alone are not sufficient, and functionality must be tested. The
systematic assessment of the complete phenotype is probably
unrealistic, and it is commonly accepted that the demonstra-
tion of at least one metabolic function, one synthetic function,
and one storage function provides sufficient evidence to define
a differentiated cell as a hepatocyte-like cell. It is much more
challenging to determine whether a cell is a true hepatocyte in
vivo. Immunostaining for albumin, cytokeratin-18 or hepato-
cyte nuclear factor 4 is a recognized indicator of hepatocyte
transdifferentiation but does not allow to asses functionality.
Models allowing cells to completely replace deficient native
hepatocytes can provide sufficient evidence of complete
functionality (Lagasse et al., 2000), although cell fusion cannot
be excluded. Other strategies include isolation of newly formed
hepatocytes followed by ex-vivo phenotype assessment or
detection of human proteins (e.g. albumin) in xenotransplan-
tation models.
In vitro, the transdifferentiation of MSCs in hepatocyte-like
cells was obtained when cells were cultured on Matrigel
with a specific medium containing several growth factors e.g.
fibroblast growth factor, epidermal growth factor, hepatocyte
growth factor (HGF), insulin, and dexamethasone (Campard et
al., 2008). Once differentiated, MSCs expressed cytoplasmic
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cytokeratin-18, connexin-32, hepatocyte nuclear factor 4,
hepatocyte-specific antigen, and dipeptidyl-peptidase IV or
cell surface markers including Thy-1, c-Kit, and Flt-3 detected
by RT-PCR or immunostaining (Hong et al., 2005; K.D. Lee
et al., 2004; Aurich et al., 2007). Similar to hepatocytes, the
differentiated MSCs stored glycogen, produced low quantities
of urea, transported low-density lipoprotein (LDL), and ex-
pressed an inducible cytochrome P450 2B6 (assessed by
RT-PCR and enzyme activity assay) (K.D. Lee et al., 2004). It
is important to note that MSCs still expressed stem cell or
mesenchymal markers such as CD90, alpha-smooth muscle
actin, vimentin, and fibronectin suggesting that complete
transdifferentiation was not achieved (Campard et al., 2008).
Among the previously cited studies (K.D. Lee et al., 2004; Li et
al., 2010; Ong et al., 2006; Piryaei et al., 2011; Aurich et al.,
2007; Campard et al., 2008; Aurich et al., 2009), MSC-derived
hepatocyte-like cells fulfill only a low functionality by
percentage (as defined by Hengstler et al. (2005)) compared
to professional hepatocytes, i.e. ranging from 8% to 23%. And
finally, it is likely that only a small fraction of MSCs underwent
into hepatocyte transdifferentiation (Lin et al., 2011).
MSCs from other sources, such as adipose tissue were also
successfully used to demonstrate hepatocyte transdiffer-
entiation. Seo et al. showed that human adipose tissue-
derived MSCs differentiated into hepatocyte-like cells by
the treatment of HGF, oncostatin M and dimethyl sulfoxide
in vitro (Seo et al., 2005). MSC-derived hepatocyte-like
cells expressed albumin and alpha-fetoprotein and showed
LDL uptake and production of urea. Others demonstrated
that umbilical cord blood-derived MSCs were also able to
differentiate into hepatocyte-like cells in vitro (Hong et al.,
2005). MSCs expressed typical hepatocyte markers and were
reported to incorporate LDL. Altogether, these experiments
suggest that certain MSC populations, either clonally expanded
or expanded as heterogenic population, independently from
tissue of origin, have the potential to transdifferentiate into
hepatocyte-like cells. Inconsistencies between studies may be
due to different isolation protocols and culture conditions
whichmay be fundamental to select growth of subpopulation of
MSCs which are more prone for genetic reprogramming
(Phinney and Prockop, 2007).
In vivo, human MSCs were reported to differentiate into
hepatocyte-like cells when transplanted during acute or
chronic liver failure in rodents (Sato et al., 2005; Kuo et al.,
2008). Human MSC xenografts were shown to rescue nonobese
diabetic immunodeficient mice from carbon tetrachloride
(CCl-4)-induced fulminant hepatic failure (Kuo et al., 2008); in
this situation 4% of the liver was repopulated by MSCs of
human origin. Further, labeled human adipose tissue-derived
MSCs were retrieved in the liver of CCl-4-injured severe
combined immunodeficiency mouse after intravenous
injection and differentiated into hepatocyte-like cells
(Seo et al., 2005). Sato et al. used a specific marker for
human Y chromosome and observed that human MSCs can
transdifferentiate in hepatocyte after xenotransplantation
by intrahepatic injection to allyl alcohol-treated rats
(Sato et al., 2005). Evidence of the ability of MSCs to
transdifferentiate and integrate into liver tissue was also
reported in larger animals. Chamberlain et al. injected
human clonally derived MSCs by an intraperitoneal or
intrahepatic route into preimmune fetal sheep in theabsence of liver injury (Chamberlain et al., 2007). The
intrahepatic injection resulted in the more efficient and
widespread generation of hepatocytes 70 days after xeno-
transplantation (13% of the hepatocytes). These experi-
ments suggested that hepatocyte-like cells issued from
MSCs could replace damaged hepatocyte and thus provide a
supportive effect in an acute or chronic liver injury
situation. Although it is possible that the microenviron-
ment of the injured liver allows appropriate conditioning
for implantation and transdifferentiation, in vivo signals
driving transdifferentiation into hepatocytes are yet not
identified. A further issue not usually discussed is pheno-
type stability, even if MSCs engraft in the injured liver and
form into hepatocyte-like cells, it is likely that chronic
injury provocation (e.g. high levels of TGF-β) precludes
those cells to stay epithelial-like. In this respect, Kisseleva
et al. showed that cells recruited from the bone marrow to
the fibrotic liver (induced by bile-duct ligation) finally
become collagen-producing fibrocytes (Kisseleva et al.,
2006). Moreover, Sato et al. showed that after a very small
increase in the percentage of MSCs that transdifferentiated
in hepatocyte-like cells in allyl alcohol-injured livers
(i.e. 0.5% at day 28 after cell transplantation), this percent-
age drops to zero at day 58 (Sato et al., 2005). Finally, MSCs
are not the only bone-marrow progenitor cell that can give rise
to hepatocytes, hematopoietic stem cells were shown to
significantly contribute to liver regeneration after acute liver
injury (Lagasse et al., 2000) and multipotent adult progenitor
cells can differentiate into hepatocyte-like cells (Schwartz
et al., 2002). The contribution of hematopoietic stem cells,
unlike MSCs, has been demonstrated to occur by cell fusion
rather than by transdifferentiation (Wang et al., 2003).Immunomodulation by MSCs
Liver injury caused by persistent inflammation is accompa-
nied with T cell, B cell and monocyte infiltration of the liver
(Kisseleva and Brenner, 2012). It has been demonstrated
that immunosuppressive therapies can prevent the recur-
rence of some liver disease before and after liver transplan-
tation (Dmitrewski et al., 1996; Manousou et al., 2010;
Mohamadnejad et al., 2005). Moreover, decreased inflam-
mation is likely to be beneficial to liver regeneration during
acute hepatocellular insufficiency (Yang et al., 2007; Sgroi
et al., 2011). In this respect, MSC immunomodulatory and
immunosuppressive properties are potentially involved in
the favorable effect of MSC transplantation in chronic
and acute liver diseases. First, MSCs are nonimmunogenic
cells. Indeed, MSCs have few MHC-I, and lack MHC-II as
well as costimulatory molecules CD80, CD86 or CD40 on
their surface, and thus fail to stimulate an allogeneic T-cell
response (Jacobs et al., 2013). Second, MSCs are immuno-
suppressive; they suppress naive and memory T lymphocyte
activation, proliferation and cytotoxicity (Uccelli et al.,
2008). In vitro, solid evidence of MSC immunosuppressive
effect was provided by Di Nicola et al. (Di Nicola et al., 2002).
Autologous and allogeneic bone marrow-derived MSCs dose-
dependently and contact-independently reduced CD4(+) T cell
proliferation and CD8(+) T cell cytotoxicity CD8(+) stimulated
by allogeneic cells, polyclonal activators (Di Nicola et al.,
2002), or specific antigen (Krampera et al., 2003). The
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HGF partially restored T cell proliferation (Di Nicola et al.,
2002). However, the role of these two growth factors was not
observed in other settings (Le Blanc et al., 2003; Tse et al.,
2003). Aggarwal and Pittenger demonstrated that MSCs exert
their immunosuppressive effects through the secretion of
prostaglandin E2 that further promoted IL-10 secretion by
dendritic cells (Aggarwal and Pittenger, 2005); this was
confirmed by others (Rasmusson et al., 2005). Moreover, MSC
caused an increase in regulatory T cells and a decrease in
tumor necrosis factor alpha (TNF-α) (produced by dendritic
cells), interferon-γ (IFN-γ) (produced by TH-1 cells), and IL-4
(produced by TH-2 cells) (Aggarwal and Pittenger, 2005).
Another candidate mediator of MSC suppressive effects
is indoleamine 2,3-dioxygenase. Meisel et al. showed that
MSC expressed indoleamine 2,3-dioxygenase upon IFN-γ
stimulation, leading to tryptophan depletion and thus
inhibition of T cell proliferation (Meisel et al., 2004);
this was further confirmed by others (Suva et al., 2008;
Sheng et al., 2008). Another important factor involved in
MSC-mediated immunomodulation is the human leukocyte
antigen (HLA)-G5 protein. Selmani et al. demonstrated
that MSCs produced soluble HLA-G5 that suppressed T-cell
proliferation and increased regulatory T cell numbers (Selmani
et al., 2008). MSC inhibitionwas also extended to B cell (Glennie
et al., 2005; Corcione et al., 2006), dendritic cells (Nauta et al.,
2006; Zhang et al., 2004; Jiang et al., 2005), and natural killer
cells (Nauta and Fibbe, 2007; Sotiropoulou et al., 2006).
The suppressive capacities of MSCs were further con-
firmed in preclinical studies. A first report by Bartholomew
et al. demonstrated that the injection of allogeneic bone
marrow-derived MSCs prolonged third-party skin graft
survival in baboon (Bartholomew et al., 2002). Other studies
used models of immune-mediated diseases and confirmed
with strong evidence that MSC can efficaciously modulate
pathogenic B- and T-cell response (Zappia et al., 2005;
Gerdoni et al., 2007; Augello et al., 2007; Urban et al.,
2008).
In clinical studies, the in vivo immunosuppressive effect
of transplanted MSCs has been successfully shown to
treat acute steroid-resistant GVHD in hematopoietic stem
cell-transplanted patients (Le Blanc et al., 2004, 2008).
One to five doses containing 1.4 × 106 MSCs (HLA-matched
or -mismatched) were infused in 55 patients, and a
complete response or improvement was observed in 71%
of them. The 2-year probability of survival was 35%, compared
to 10% in historical series (Ringden and Nilsson, 1985; Deeg,
2007). Of note, the response to MSC treatment was not
restricted to single organs: skin, gastrointestinal tract, and
liver GVHD were significantly decreased (e.g. MSC decreases
liver mononuclear cell infiltration and endothelialitis (Tobin et
al., 2013)). Of note, no patients had acute or late side-effects
(considering a median follow-up of 16 months). MSC effect
has been attributed to the inhibition of donor T-cell reactivity
to histocompatibility antigens of the recipient tissues. A
possible drawback could be that infused MSCs might impair
the therapeutic graft-versus-leukemia effect by recipient
T-cell and increase the incidence of leukemia relapses (Ning
et al., 2008).
Another clinical trial taking advantage of MSC immuno-
modulatory effects showed that autologous MSC infusion was
effective as an induction therapy in kidney recipients (Tan etal., 2012). This therapy allowed reducing acute rejection
rate, decreasing the risk of opportunistic infection, and
increasing estimated renal function at 1-year confirming the
immunosuppressive capacities of MSCs in human. These
promising results open the path to the use of MSCs in liver
transplanted patients (Popp et al., 2009).
Regardless of the definitive elucidation of the underlying
mechanisms, these investigations suggest that MSCs have
effective immunosuppressive properties that could theoret-
ically participate in the reduction of leukocyte infiltration
during acute and chronic liver injuries, and after liver
transplantation.Cytokines secreted by MSCs during liver injury
Chemokines and cytokines secreted by MSCs might be
effective in reducing inflammation and hepatocyte apoptosis
in both acute and chronic liver injuries. MSC-derived cytokines
that were shown to improve liver injury are summarized in
Fig. 1. In a rat model of D-galactosamine-induced acute
liver injury, Parekkadan et al. showed that human bone
marrow-derived MSC-conditioned medium injection, or an
extracorporeal perfusion using a bioreactor containing MSCs,
provided a significant survival benefit in the treated animal
compared to controls (Parekkadan et al., 2007a). Although no
specific mechanism of action has been identified, the authors
suggested an effect on immune cell migration to the liver,
and postulated that soluble factors may be implicated in
the observed effects. Potential candidates included vascular
endothelial growth factor (Zhen et al., 2010), HGF, insulin-like
growth factor binding proteins (Leu et al., 2003), or IL-6. In a
subsequent study using the same model of liver injury van
Poll et al. observed that administration of MSC conditioned
medium down-regulated blood levels of IL-1β, TNF-α and IL-6,
increased levels of IL-10 (van Poll et al., 2008). This was
accompanied with a lower lymphocyte infiltration in the liver,
a reduced hepatocyte apoptosis and an increase in hepatocyte
proliferation.
MSCs were shown to secrete epidermal growth factor that
could promote hepatocyte proliferation and function during
liver regeneration (Natarajan et al., 2007). MSCs were also
shown to reduce the proliferation of stellate cells and
collagen type I synthesis through the secretion of TNF-α
(Parekkadan et al., 2007b), and to promote hepatic stellate
cell apoptosis through the secretion of nerve growth factor
(Lin et al., 2009). Higashiyama et al. suggested that MSCs
mediate an antifibrotic effect through the expression of
matrix metalloproteinase-9 that degrades the extracellular
matrix (Higashiyama et al., 2007). There are probably other
anti-inflammatory cytokines implicated, for example, some
MSC subpopulations were shown to secrete IL-1 receptor
antagonist and thus reduced fibrosis (Ortiz et al., 2007).
However, MSCs did not only promote anti-inflammatory
signals, they also secreted proinflammatory cytokines such
as TGF-β 1 and 3, IL-6, monocyte chemoattractant protein-1,
macrophage inflammatory protein-1α and β or monokine
induced by IFN-γ (van Poll et al., 2008; Salazar et al., 2009;
Boomsma and Geenen, 2012). Interestingly, it has been
suggested that depending upon selective toll-like receptor
activation, MSCs can polarize into two different phenotypes:
the TLR4 activation promoting mostly proinflammatory
Figure 1 MSC-derived cytokines that potentially protect the liver during injury. 1. Aggarwal and Pittenger Blood 2005, Rasmusson
et al. Exp Cell Res 2005. 2. Ortiz et al. Proc Natl Acad Sci USA 2007. 3. Di Nicola et al. Blood 2002, Parekkadan et al. PLoS One 2007. 4.
Parekkadan et al. PLoS One 2007, Zhen et al. Cytotherapy 2010. 5. Parekkadan et al. PLoS One 2007. 6. Parekkadan et al. Biochem
Biophys Res Commun 2007. 7. Lin et al. Life Sci 2009. 8. Higashiyama et al. Hepatology 2007.
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pressive ones (Waterman et al., 2010). In summary, MSC
cytokine secretion is likely to reduce inflammation and to
promote liver regeneration during acute and chronic liver
injuries. However, exact mechanisms are unknown and MSC
cytokine secretion could be proinflammatory in some
circumstances.
MSC transplantation in animal models of liver
injury
Hereafter, we will discuss the main findings regarding MSC
transplantation in animal models of acute and chronic liver
injuries.
Acute liver injury
Numerous studies tried to demonstrate the therapeutic
potential of MSCs in the treatment of acute liver failure. A
few studies showed beneficial effects. Using a model of
carbon tetrachloride induced acute liver failure in immuno-
deficient mice Kuo et al. showed that intrasplenically or
intravenously transplanted human MSCs engrafted into
recipient liver, differentiated into functional hepatocytes,
and rescued liver failure (Kuo et al., 2008). Similarly,
intravenously injected human MSCs derived from adipose
tissue also improved liver functions (i.e. decreased levels of
ammonia, uric acid, alanine transaminase, and aspartate
transaminase) in nude mice with CCl-4-caused liver injury
(Banas et al., 2008). Soluble factors possibly responsible for
this effect were numerous and included: IL-1R-alpha, IL-6,
IL-8, granulocyte colony-stimulating factor, granulocytemacrophage colony-stimulating factor (GM-CSF), monocyte
chemotactic protein-1, nerve growth factor, and HGF. More
recently, in a rat model of hepatic ischemia–reperfusion
injury, it has been observed that rat MSCs inhibited
hepatocellular apoptosis and stimulated regeneration
suggesting a favorable bystander effect of MSCs during
acute liver injury (Kanazawa et al., 2011). More recently,
rat bone marrow-derived MSC infusion was shown to
reduce aspartate transaminase, alanine transaminase and
alkaline phosphatase in rats with acute CCl-4 liver injury
(L. Zhao et al., 2012). These studies have established the
proof of principle in small animals, but the elucidation of
mechanisms involved in the observed effect remained
elusive. Studies on large animal models are sparse and
to our best knowledge a few studies were performed on
pigs. A validation in a large animal model is requested by
many national regulatory agencies before starting clinical
application, as for other innovative and invasive therapies
such as xenotransplantation. Allotransplantation of bone
marrow-derived MSCs significantly enhanced liver hyper-
plasia after selective portal vein ligation in pigs (Liska et
al., 2009). This result was attributed to bystander effects
of the transplanted MSCs as only few cells were detected in
recipient livers two weeks after the infusion. Moreover,
transaminases remained at high levels after MSC injection,
indicating that the transplanted MSCs were not sustaining
liver function. This might be due to the small number of
cells that were reported to engraft in the liver tissue. Li et
al. transplanted human bone marrow-derived MSCs in pigs
with fulminant liver failure induced with D-galactosamine,
and receiving no immunosuppression (Li et al., 2012). Thirty
million human MSCs were infused intraportally or through
peripheral veins. Thirteen of the 15 animals with intraportally
1354 R.P.H. Meier et al.injected MSCs achieved long-term survival (N6 months),
whereas no animal injected with MSCs in peripheral veins
or sham injected survived. Up to 30% of the hepatocytes
were bone marrow-derived MSC-derived during the early
weeks following the procedure. Cao et al. transplanted
human placenta-derived MSCs in miniature pigs with
D-galactosamine-induced acute liver failure (Cao et al.,
2012). MSC-treated animals had improved transaminases
and bilirubin levels in the serum. Transplantation of human
MSCs via the portal vein reduced liver inflammation,
promoted liver regeneration and improved survival, where-
as transjugular MSC injection did not. Human albumin
and cytokeratin 18 positive cells were detected in
recipient's liver 5 months after transplantation. Of note,
only transplanted animals were immunosuppressed; this
probably precludes a strict comparison with nontransplanted
animals. Altogether, these experiments have shown positive
effects in the large animal model, but again, no underlying
mechanism was so far identified.
Some other studies on mice and rats testing MSC
transplantation reported either no effect or effects which
could potentially be harmful. After intrahepatic injection
of human bone marrow-derived MSC transplantation into a
mouse model of acute liver injury induced by 2/3 hepatec-
tomy, MSCs expressed alpha smooth muscle actin and
merged with collagen deposition suggesting that MSCs are
able to adopt a fibrogenic phenotype (Baertschiger et al.,
2009). These results were confirmed by other reports
wherein MSCs adopted a myofibroblast-like shape after
transplantation in a model of acute liver injury (di Bonzo et
al., 2008). This fibrogenic potential may be related to the
high expansion of MSCs; it is possible that some clones are
prone to differentiate into fibroblast-like cells and thus
contribute to the fibrotic process of the injured liver.
Overall, in the situation of acute liver injury, MSC trans-
plantation might lead to unwanted effects and contribute to
the fibrotic reaction.Chronic liver injury
MSCs have also been tested to reduce fibro-inflammatory
reactions, and several studies reported that MSCs inhibit
the progression of liver fibrosis. Fang et al. injected bone
marrow-derived MSCs from male BALB/c mice intravenously
into female BALB/c mice with CCl-4-induced liver fibrosis
and observed reduced hydroxyproline levels in the serum,
and fewer histological signs of hepatic necrosis when
compared to controls (Fang et al., 2004). In this study MSCs
engrafted into host's liver at low frequency suggesting a
bystander effect. Similarly, others showed that rat bone
marrow-derived MSC transplantation decreased collagen
expression and liver hydroxyproline content (Abdel Aziz et
al., 2007) and restored albumin production in rats with
chronic CCl-4 liver injury (Oyagi et al., 2006). Human
umbilical cord-derived MSCs (Tsai et al., 2009; Yan et al.,
2009) and human placenta-derived MSCs (Lee et al., 2010)
also mediated anti-fibrotic effects. More recently in vitro
pre-differentiated hepatocyte-like cells were successfully
used to treat experimental liver fibrosis (Piryaei et al., 2011;
Mohsin et al., 2011). In these studies the authors reported
that MSCs predifferentiated into hepatocyte-like cells weremore efficient for preventing liver fibrosis. On the contrary,
Tsai et al. observed favorable effects in the absence of MSC
transdifferentiation (Tsai et al., 2009). Human umbilical
cord-derived MSCs were directly injected into fibrotic livers
of rats wherein MSCs engrafted and exerted their effect
without transdifferentiation into hepatocytes. As suggested
above, MSCs could exert their antifibrotic effects through
secretion of matrix metalloproteinases (Higashiyama et al.,
2007; Chang et al., 2009; Hardjo et al., 2009). These
enzymes are normally upregulated during liver fibrosis in
response to collagen accumulation, an increase in their
activity could allow to a more efficient degradation of
extracellular matrix. Zhao et al. observed an increase in
the level of anti-inflammatory cytokines such as IL-10 and
decreased levels of inflammatory cytokines such as IL-1β,
IL-6, TNF-α and TGF-β in mice treated with intravenous
infusion of MSCs (W. Zhao et al., 2012). Thus, MSCs may
specifically and nonspecifically reduce local inflammation,
providing a protection against chronic liver injury. In summary,
protective effects of MSC transplantation on liver fibrosis have
been shown in rodents, but again, the supposed mechanisms of
action are not fully understood.
Several studies failed to observe significant beneficial
effects of MSCs in chronic liver injury model. Some studies
even indicated that MSCs might contribute to the fibrotic
tissue. In a rat hepatic injury model with prolonged CCl-4 or
allyl alcohol treatment, Popp et al. showed that MSCs
injected into the portal vein or directly into the liver
engrafted less efficiently compared to injected hepato-
cytes, and did not contribute to liver regeneration (Popp et
al., 2007). Carvalho et al. observed unchanged transami-
nase levels, albumin levels, and liver fibrosis area between
rats transplanted with rat bone marrow-derived MSCs and
controls (Carvalho et al., 2008). Similar negative results
were reported with human cord blood-derived MSCs injected
through tail vein of rats with thioacetamide-induced liver
fibrosis (Kim et al., 2011). MSCs engrafted into the liver but
did not acquire mature hepatic phenotype. No differences
were observed in biochemical markers or in the extent of
liver fibrosis. di Bonzo et al. using intravenously transplanted
human bone marrow-derived MSCs showed their potential to
engraft into normal and CCl-4-injured liver parenchyma,
however, according to morphologic examination, detection
of albumin, alpha-fetoprotein, and cytokeratin 18, there
was a very low number of transdifferentiated MSCs into
hepatocyte-like cells (less than 0.3% of the cells) (di Bonzo et
al., 2008). The detection of MSCs expressing alpha smooth
muscle actin further lead di Bonzo et al. to point out a possible
fibrogenic potential of MSCs. Another concern is the fact
that in the absence of transplantation, native bone marrow-
derivedMSCs canmigrate and engraft into damaged liver (Li et
al., 2009). This phenomenon was shown to be dependent
upon sphingosine 1-phosphate gradient and sphingosine
1-phosphate receptor type 3. In humans, the hypothesis that
bone marrow-derived cells could contribute to liver fibrosis
was confirmed in patients with liver fibrosis following sex
mismatched transplantation. Analysis of livers from female
donors transplanted in male patients, or livers of female
patient who received a male bone marrow transplant
showed that 7 to 22% of the liver fibrosis-related
myofibroblasts contained the Y chromosome (Forbes et al.,
2004), suggesting a bone marrow origin of myofibroblasts in
Figure 2 The number of trials per year registered on www.
clinicaltrials.gov transplanting mesenchymal stem cells in
patients from 2004 to 2012.
A search on www.clinicaltrials.gov (March 2013) with the term
“mesenchymal stem cells” listed 271 trials from 2004 to 2012
(i.e. not including 2013).
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mice transplanted with sex mismatched bone marrow dem-
onstrated that in the cirrhotic liver, the contribution of bone
marrow to parenchymal regeneration was minor (0.6% of
hepatocytes), and by contrast, the bone marrow contributed
to 68% of the hepatic stellate cell pool and 70% of
myofibroblast populations (Russo et al., 2006). These studies
demonstrate that MSCs might have negative effects, and
suggest that there might be various MSC subpopulations with
opposite effects.
MSCs are isolated and cultured under varying conditions
which probably profoundly affects their plasticity and
function. The different conditions during which MSCs are
transplanted are likely to be the cause of conflicting results
regarding engraftment rate and protective effects on liver
fibrosis.
Clinical trials using MSCs for the treatment of
liver diseases
Despite controversial results in experimental animal models,
numerous clinical studies have been initiated to investigate
the therapeutic potential of MSCs. A search on http://www.
clinicaltrials.gov (March 2013) with the terms “mesenchymal
stem cells” listed 282 trials (Table 1). Sixty-two were
completed (22%), 146 were recruiting (52%), 28 were not yet
recruiting (10%), and 46 were at undetermined stage (16%).
These trials included 166 phase 1 (59%), 71 phase 2 (25%),
and 11 phase 3 trials (4%); 34 were undetermined (12%). The
number of trials per year increased almost exponentially
from 2004 to 2012 (Fig. 2). Investigators used or are using
culture-expanded allogeneic or autologous MSCs, originat-
ing either from their own cell isolation center or from a
commercial origin (e.g., Prochymal®). Among these 282
trials, 28 concern the use of MSCs in the treatment of liver
diseases (22 in cirrhotic patients and 6 in patients with
acute liver failure).Table 1 Investigations using MSC transplantation in humans.
A search on www.clinicaltrials.gov (March 2013) with the term “mese
com (March 2013) with the terms “mesenchymal stem cells” [title
Clinical Trial, Humans, with an additional search with the terms “
filter) listed 81 studies.














Investigations using MSC transplantation in humans.We found seven published clinical trials studying the
effects of MSC transplantation in patients with liver cirrhosis
(listed in Table 2). A pilot phase 1 study published in 2007
included four patients with decompensated liver cirrhosis
(Mohamadnejad et al., 2007). Cells were derived from iliac
crest puncture and expanded in culture during 73 days
with 2.5 passages on average. Thirty-two million autologous
MSCs were administrated through a single injection into
the cubital vein of the arm. No severe side-effects were
observed until the end of the follow-up at 12 months after
the transplantation. Three out of four patients improved
their Model for End-Stage Liver Disease (MELD) scores at
6 months after transplantation and two of them continued
to improve up to 12 months. In another pilot phase 1 study,
30 to 50 million autologous iliac crest-derived MSCs werenchymal stem cells” listed 282 trials; a search on www.pubmed.
] or “mesenchymal stem cell” [title] with filters activated for
mesenchymal stem cells” [title] and “trial” [title] (without














1356 R.P.H. Meier et al.injected in the peripheral or portal vein of eight patients
with end-stage liver disease (Kharaziha et al., 2009). The
treatment was well tolerated and the average MELD score
among patients improved from 18 to 11 after 24 weeks. In a
phase 2 study, Amer et al. randomized 40 patients with
end-stage liver failure due to chronic hepatitis C into two
groups of 20 patients: the first group received autologous
bone marrow-derived MSCs previously transdifferentiated in
hepatocyte-like cells in vitro, the second group received
standard supportive treatment (Amer et al., 2011). The
patients receiving MSCs had significant improvement in
Child–Pugh and MELD scores appearing after 2 weeks and
maintained for 6 months when compared to 20 patients who
received traditional supportive treatment. Scores measured
by fatigue scale and performance status were also improved.
Patients receiving MSCs through intrahepatic route had
pronounced stronger improvement of MELD and fatigue
scores compared to MSCs infused through intrasplenic
route. In a phase 2 trial, Peng et al. transplanted autologous
MSCs from iliac bone aspirates in 53 patients with liver
failure caused by hepatitis B virus infection (Peng et al.,
2011). Levels of albumin, bilirubin, prothrombin time and
MELD score were improved at two to three weeks after
MSC transplantation, compared with 105 control-patients.
Long-term follow-up revealed similar results between groups
in terms of hepatocellular carcinoma incidence and mortal-
ity. In another phase 2 trial, El-Ansary et al. transplanted
autologous iliac bone-derived MSCs in patients with hepatitis
C-related cirrhosis and MELD score N12 (El-Ansary et al.,
2012). Fifteen patients received 1 million MSCs per
kg-weight intravenously and were compared to 10 patients
with conventional supportive treatment. Follow-up of
MSC-transplanted patients at 3 and 6 months showed a
significant improvement in serum albumin, prothrombin,
and total bilirubin levels, resulting in an improved MELD
score. In this study, there was no difference in curative
potential between MSCs and MSC-derived hepatocyte-like
cells. More recently, in phase 2 trial Zhang et al. randomized
(2:1) 46 patients with chronic hepatitis B receiving either
three injections with 0.5 million/kg allogeneic umbilical
cord-derived MSCs (n = 31) or saline solution (n = 15) (Zhang
et al., 2012). Patients receiving MSC infusion had improved
MELD score, ascites and fibrosis marker levels up to
48 weeks after the treatment. The major concerns of this
study are the lack of evidence that the patients have been
given appropriate conventional anti-viral therapy and the
absence of explicit data about the course of illness before
inclusion, the virus genotype, or the length of abstinence
from alcohol. A common problem in these studies was
the lack of data regarding the MSC's fate once injected
into the body. Gholamrezanezhad et al. addressed this
issue and injected 111In-oxine-labeled human bone marrow-
derived MSCs in a peripheral vein of cirrhotic patients
(Gholamrezanezhad et al., 2011). They observed an initial
accumulation of MSCs in the lungs with a peak 20 min after
injection, followed by a decrease of the lung signal and a
gradual increase in the liver and spleen signal that was
detected up to 10 days after injection (111In half-life is 67 h),
indicating that MSCs do not only entrap in the lungs, but also
migrate to the liver following peripheral intravenous injec-
tion. Terai et al. transplanted an average of 70 million/kg
unsorted bone marrow mononuclear cells from bone marrowaspirates (including other stem cell types as hematopoietic
stem cells, MSCs, multipotent adult progenitor cells (Jiang
et al., 2002)) in cirrhotic patients (Terai et al., 2006). This
therapy allowed an improvement in serum albumin levels,
Child–Pugh scores, alpha-fetoprotein levels and liver prolif-
erating cell nuclear antigen up to 24 weeks after transplan-
tation. Similar observations reported improvements with the
infusion of unsorted bone marrow cells in cirrhotic patients
(Amin et al., 2006; Lyra et al., 2007, 2010; Kim et al., 2010)
and no improvement in patients with alcoholic steatohepatitis
(Spahr et al., 2013). The pilot studies mentioned above
suggested that autologous MSC infusion allows mild biolog-
ical improvements in patients with liver diseases, but clear
and significant clinical benefit was not yet reported. To our
knowledge, none of these studies provided histologic
evidence of improvement with MSC treatment. Of note,
intraportal infusion seemed to be more efficient than
peripheral route (Amer et al., 2011), and differentiation
toward hepatocytes prior to infusion seemed not to increase
MSC curative potential (El-Ansary et al., 2012). Overall,
evidences provided by most of these clinical studies are
quite poor. The cells are often poorly characterized; and
improvements are claimed where there are insufficiently
powered experimental/control groups, or lack of random-
ization to make this claim.
Finally, the mechanisms allowing MSCs to improve clinical
parameters in liver disease are largely unknown. For example,
it is not knownwhether MSC transplantation allows a significant
reduction of liver fibrosis and whether these biological and
clinical improvements have a significant impact on outcomes
such as the patient's need for transplantation and survival.
Furthermore, the long-term risk of developing malignancies
should be evaluated.Potential risks of MSC therapies
Tumorigenic potential of MSCs
Some concerns have been raised regarding MSC susceptibility to
undergo malignant transformation or to promote pre-existing
tumor growth. In order to obtain a sufficient number of MSCs
prior to transplant, cells undergo extensive in vitro expansion,
which increases the risk for genetic mutations, eventually
leading to malignant transformation. After several passages
(N3) murine MSCs accumulate chromosomal aberrations and
spontaneously transform into malignant cells (e.g. sarcoma)
in vitro and in vivo (Zhou et al., 2006; Miura et al., 2006; Li
et al., 2007; Aguilar et al., 2007; Tolar et al., 2007). In
contrast, after a few number of passages, human MSCs
become senescent without any signs of immortalization
both in vitro (Miura et al., 2006; Bernardo et al., 2007) and
in vivo (Kim et al., 2009). Rubio et al. suggested that MSC
could form tumors (Rubio et al., 2005). But it turned out
that this was due to a cross-contamination with a cell line
used in their laboratory (Garcia et al., 2010). Human MSCs
seem to be at lower risk of malignant transformation.
However, at very high passages (N170) MSCs may display
telomeric deletions (Dahl et al., 2008); thus, analysis of
chromosomal integrity prior to MSC transplantation could
improve the safety of the procedure. Further, microsatel-
lite instability, down-regulated genes involved in DNA
Table 2 Phase 1–2 studies using MSC transplantation to treat chronic liver diseases.
A search on www.pubmed.com (March 2013) with the terms “mesenchymal stem cells” [title/abstract] and “patients” [title/abstract] AND (“cirrhosis” [title/abstract] or “end-stage
liver” [title/abstract]) with filters activated for Clinical Trial, Humans. Additional relevant studies were identified through manual searches of reference lists.









Arch Iran Med 2007
Phase 1, open, safety Decompensated liver
cirrhosis (Cryptogenic,
n = 3, autoimmune, n = 1)
Autologous, iliac crest No Cubital vein of the arm 4
Kharaziha et al. Eur J
Gastroenterol Hepatol 2009
Phase 1, open, safety Liver cirrhosis (cryptogenic,
n = 2, hepatitis C, n = 1,
hepatitis B, n = 3, alcoholic, n = 1)
Autologous, iliac crest No Peripheral or portal vein 8
Amer et al. Eur J
Gastroenterol
Hepatol 2011
Phase 2, open, safety,
randomized
Child C due to chronic
hepatitis C




Peng et al. Hepatology
2011
Phase 2, open, safety Chronic liver failure caused
by hepatitis B virus
Autologous, iliac crest No Proper hepatic artery 53
El-Ansary et al. Stem
cell reviews 2011
Phase 2, open, safety Hepatitis C-related cirrhosis
and MELD score N12
Autologous, iliac crest Both Peripheral vein 15
Gholamrezanezhad et
al. Nucl Med Biol 2011
Phase 1, open, safety Decompensated liver cirrhosis
(cryptogenic, n = 3,
hemochromatosis, n = 1)
Autologous, iliac crest No Peripheral vein 4
Zhang et al. J Gastroen
Hepatol 2012
Phase 2, open, safety,
randomized (2:1)
Chronic hepatitis B
patients (n = 46)
Allogeneic, umbilical
cord-derived





























Arch Iran Med 2007
0 32 mio None MELD score, serum
creatinine
MELD score and serum creatinine
improved at 6 and 12 months
Kharaziha et al. Eur
J Gastroenterol
Hepatol 2009
0 30–50 mio None MELD score MELD score improved from 18 to 11
after 24 weeks
Amer et al. Eur J
Gastroenterol
Hepatol 2011






Child score and MELD score
improved after 2 weeks and maintained
for 6 months. Better score in fatigue
scale and performance status
Authors found a better curative
potential with MSCs infused
through the intrahepatic route
Peng et al.
Hepatology 2011
105 10 mio None MELD score, serum
albumin
MELD score was improved at two to
three weeks after MSC transplantation
Long-term follow-up revealed
similar results between groups
in terms of hepatocellular
carcinoma incidence and mortality




Not reported MELD score, serum
albumin
MELD score and albumin were improved
at 3 and 6 months after MSC
transplantation
Authors compared MSCs to
MSC-derived hepatocyte-like cells
and found no difference in
curative potential
Gholamrezanezhad
et al. Nucl Med
Biol 2011
0 270–400 mio None MSC engraftment,
MELD score
MSC engrafted mainly in liver and spleen
No significant improvement in liver function
was noted after a 1 month period
The study was designed to trace
MSC once injected













MELD score, ascites, serum laminin,
hyaluronic acid, procollagen type III, and
type IV collagen were improved up to
48 weeks after MSC transplantation
MELD Na scores were simultaneously
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observed in human MSCs (Oliveira et al., 2011). Moreover,
the risk of tumorigenicity due to MSCs might be increased in
patients receiving immunosuppression after liver transplan-
tation with a previous MSC infusion.
A further potential risk of MSC transplantation is to
promote the growth of masked pre-existing tumors or pre-
cancer lesions, especially in immunosuppressed patients.
In animal studies, co-transplanting MSCs with cancer cells
promotes the growth of the neoformed tumors and their
metastatic potency (Karnoub et al., 2007; Ramasamy et
al., 2007; Bian et al., 2010; Kucerova et al., 2010). The
mechanisms include the secretion of growth factors
(i.e. TGF-β, HGF, and epidermal growth factor) which
promote tissue growth and neo-vascularization (Zhu et al.,
2006). This is not the case with every tumor, Cousin et al.
highlighted long-lasting inhibition of tumor growth on
aggressive pancreatic cancer cells implanted in vivo
(Cousin et al., 2009). MSCs also showed effects on
preestablished tumor growth in animal models either
promoting (Hung et al., 2005; Beckermann et al., 2008;
Lin et al., 2010; Sun et al., 2005) or inhibiting tumor
growth (Khakoo et al., 2006; Dasari et al., 2010a,b;
Secchiero et al., 2010). However, all studies reporting
that MSCs promote tumor growth either used immortalized
or modified MSCs (Casiraghi et al., 2013) and may not
reflect properties of primary MSCs. Safety results of a pool
of 700 subjects who received autologous or third party
MSCs showed that none of them had major side effects, nor
included the development of hematopoietic or solid tumors
(Casiraghi et al., 2013). However, in most clinical trials the
follow-up was relatively short (1 month to 6.8 years), and the
occurrence of a tumor may take longer to appear. However, a
correlation between cotransplantation of MSCs together with
hematopoietic stem cells and higher incidence of relapses in
patients with hematologic malignancy has been observed
(Ning et al., 2008). Therefore, MSC expansion should be
limited to keep tumorigenic risk low. Further, autologous
or allogeneic MSC transplantation should not be considered
if the donor is bearing a genetic disease associated with a
tumorigenic risk (European-Union-Group-on-Ethics, 2004),
and patients with known preexisting tumor should not undergo
MSC therapy. Although evidence coming from pilot studies
using MSCs is reassuring, risks need to be evaluated on a
long-term basis.
Viral transmission by MSCs
In contrast to MSC autotransplantation, MSC allotransplantation
(i.e. in the treatment of GVHD after hematopoietic stem cell
transplantation (Le Blanc et al., 2008) or chronic liver diseases
(Zhang et al., 2012)) may carry the risk of viral transmission to
the recipient. MSCs were shown to be permissive for herpes
simplex virus and cytomegalovirus infections in vitro, but
not for Epstein–Barr virus infection (Sundin et al., 2006).
Parvovirus B19 was detected in cultured MSCs of 5% of healthy
donors and varicella zoster virus in 11% (Rollin et al., 2007),
suggesting that a risk is present. Furthermore, viral transmission
of parvovirus B19 to bone marrow cells was demonstrated in
vitro (Sundin et al., 2008). However, patients transplanted with
allogeneic B19-positive MSCs did not develop viremia or
symptomatic B19 infection. Sundin et al. concluded thatB19-positive MSCs carry a low pathogenicity risk in these highly
immunosuppressed individuals (Sundin et al., 2008); however
no information was available on herpes simplex virus and
cytomegalovirus transmission by MSCs in vivo. In this context, it
seems prudent to screen both recipient and MSC donor for
parvovirus B19, herpes simplex virus and cytomegalovirus as
they can lead to dramatic infections in immunosuppressed
patients.Conclusions
MSC transplantation has recently gained widespread enthu-
siasm particularly in the perspective to use them to treat
acute and chronic liver diseases. Currently, there are
conflicting data in small animals regarding MSC efficiency
to sustain liver function and to reduce inflammation. Crucial
points governing success of MSC therapeutic potential seem
to be the type of liver injury as well as the subpopulation of
MSC chosen (Waterman et al., 2010). Unwanted effects such
as myofibroblastic transdifferentiation of the transplanted
MSCs may be influenced by subpopulation of MSCs, the route
of injection as well as the recipient. Time frame of
treatments might be important as well, i.e. injected MSCs
may directly participate to fibrogenesis during the “injury”
phase and accelerate healing process during the “resolu-
tion” phase (Kisseleva and Brenner, 2012). Only few reports
in large animals showed that MSCs can decrease the severity
of acute liver failure, and to our best knowledge, experi-
mental liver fibrosis in large animals is not an established
model. Nevertheless, several clinical trials have been
initiated, mainly in patients with no options for other
treatments. Few studies were published, and most of them
had poorly defined endpoints, rendering therapeutic bene-
fits difficult to evaluate. A common finding in these studies
was that MSC infusions reduce MELD score in patients with
end-stage liver disease. The most likely mechanism that
could explain this favorable effect appears to be the ability
of MSCs to reduce inflammation and to promote endogenous
repair rather than to directly replace hepatocytes.
To date, safety studies in humans do not have extended
follow-up in particular with respect to the evaluation of MSC
tumorigenic potential. Investigations described in this
review were certainly validated by institutional ethics
committees; however, not only registered- and university
affiliated-investigators use MSCs in humans for clinical
applications (Anon., 2012), therefore it remains important
to obtain national regulatory agency approval to warrant
maximal safety in the clinical environment (Prockop and
Olson, 2007). Questions regarding efficacy, safety and
mechanisms of action may be answered by a highly regulated
large-scale multicenter study. In conclusion, the prospect of
using MSCs as cell therapy for treating liver diseases is
encouraging but will require an improved understanding of
the mechanism behind their therapeutic effects and a
stronger validation in preclinical and clinical settings.Authorship
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